LEO Pharma A/S, a global leader in medical dermatology, today announced new long-term results from EFFISAYIL® ON, an ongoing ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Picankibart is a recombinant anti-interleukin 23p19 ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection. Botulinum toxin A (BoNT-A) injection emerged as an effective therapy for patients ...

Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...

Join Drs Steven Feldman and Bernard Vrijens as they discuss the theory and practice of improving treatment adherence for ...

The webinar will be broadcast via Zoom. Interested participants can register using the following LINK. The discussion will provide an in-depth exploration of the plaque psoriasis landscape, current ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis Foundation ...

NEW YORK (Reuters Health) - Injections of a protein called interleukin-4 (IL-4) seem equal to the best therapy now available for relieving symptoms of the chronic skin condition psoriasis, the results ...